From June 22 to 25, the 2026 BIO International Convention (BIO 2026) was held at the San Diego Convention Center. Henlius participated in the convention for the eighth consecutive year. The company's management team, including Chief Executive Officer Dr.Jason Zhu, President Wei Huang, Chief Business Development Officer and Senior Vice President Ping Cao, Chief Scientific Officer Dr.Jijun Yuan, and Chief Commercial Officer of International Markets, Darius Panaligan, attended the event and engaged in in-depth discussions with global industry partners on innovative R&D, international development, and diversified collaboration.

During the convention, Henlius showcased its early-stage innovative assets and differentiated pipeline at Booth #5841. The company held more than 150 business meetings with global biopharmaceutical companies, investors, and industry partners to explore opportunities for innovation-driven collaboration, further expand its global partnership network, and accelerate the international development and value realization of its innovative assets.

Following years of global expansion, Henlius has established an integrated global operating platform. To date, the company has obtained approvals for 10 products in more than 60 countries and regions, benefiting over one million patients worldwide. Henlius has also established long-term partnerships with leading global pharmaceutical companies, including Abbott, Accord, Dr. Reddy's, Eurofarma, Organon, Sandoz, and Eisai.

Henlius' self-developed anti-PD-1 mAb serplulimab (trade name in Europe: Hetronifly^®) has now been approved in more than 50 markets worldwide, with a recent approval in China for perioperative treatment of gastric cancer. In Europe, the product continues to expand its treatment footprint. Following its approval for extensive-stage small cell lung cancer (ES-SCLC), serplulimab received three EU approvals in 2026 for first-line treatment in non-squamous non-small cell lung cancer (nsqNSCLC), esophageal squamous cell carcinoma (ESCC), and squamous non-small cell lung cancer (sqNSCLC). It has also been included in reimbursement systems across more than 10 European countries, including the United Kingdom, Austria, Denmark, Germany, Ireland, Italy, Spain and Sweden.

Henlius' self-developed trastuzumab biosimilar (trade name: HERCESSI^™ in the U.S., Zercepac^® in Europe) has been approved in more than 50 markets worldwide. Together with company's pertuzumab biosimilar POHERDY^®, it forms the first China-developed trastuzumab–pertuzumab dual HER2-targeted regimen approved in China, the United States, and Europe, further strengthening the company's leading global breast cancer portfolio across the full continuum of care and a broad range of disease settings.

More recently, company's self-developed denosumab injections in two formulations have been commercially launched in markets including the U.S., and Canada, further expanding global access to bone health therapies. Meanwhile, the company continues to accelerate the international expansion of HLX04 (bevacizumab biosimilar) and HLX01 (rituximab biosimilar), bringing these products to more international markets and further improving patient access worldwide.

Henlius continues to accelerate the development of its innovation pipeline. Dulpatatug (HLX22), a novel-epitope anti-HER2 mAb targeting a distinct HER2 epitope, has advanced into a global multicenter phase 3 clinical trial. The study in HER2-positive advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) is currently underway across China, the U.S., Europe, Japan, Australia, Argentina, and other countries and regions. The company is also advancing the global development of HLX43, a PD-L1 ADC with "best-in-class" and broad therapeutic potential. To date, more than 1,200 patients have been enrolled globally across multiple solid tumor indications, including non-small cell lung cancer (NSCLC), with multiple international multicenter clinical studies ongoing across China, Europe, the United States, Japan, and Australia. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, key subgroup results from the NSCLC study were released in a rapid oral presentation, further demonstrating the clinical potential of HLX43 in the treatment of patients with previously treated NSCLC.

Beyond individual assets, Henlius continues to expand its innovation portfolio across next-generation molecular modalities, including ADCs, multispecific antibodies, T-cell engagers (TCEs) and fusion proteins. The company has established multiple proprietary technology platforms, including its Next-generation IO Platform, T-cell Engager (TCE) Platform, Hanjugator^™ ADC Platform, and HAI Club AI-driven drug discovery platform. The Next-generation IO platform has yielded more than seven innovative assets, while the proprietary TCE platform has advanced over five candidates into the pipeline, including HLX3901 (DLL3 × DLL3 × CD3 × CD28 tetraspecific antibody) and HLX3902 (STEAP1 × CD3 × CD28 trispecific antibody).

Leveraging the Hanjugator^™ ADC platform, Henlius has generated more than twelve next-generation ADC candidates with first-in-class or best-in-class potential, including HLX48 (c-MET × EGFR bispecific ADC), HLX49 (HER2 biparatopic ADC), HLX403 (CDH17 ADC), HLX402 (ADAM9 ADC), and HLX85 (ALPP/ALPPL2 ADC), with multiple programs rapidly progressing toward clinical development. Supported by its integrated innovation platforms and global development capabilities, Henlius continues to build a globally competitive innovation portfolio that creates new opportunities for international collaboration and delivers greater value to patients worldwide.

As its global product portfolio continues to expand, Henlius is entering a new phase of international development. Alongside deepening strategic licensing partnerships, the company is accelerating the establishment of its own overseas commercialization capabilities. Leveraging its integrated global operating platform, Henlius is strengthening commercial infrastructure in key international markets to maximize the long-term value of its innovative medicines worldwide.

Looking ahead, Henlius will remain committed to addressing unmet patient needs through continuous innovation and global collaboration, bringing more quality and affordable biologic therapies to patients worldwide.